Krazati

BMS
Marketing

FDA blasts Bristol Myers over misleading Krazati efficacy claims

The FDA has taken Bristol Myers to task for making false or misleading claims about the efficacy of Krazati on the website for the KRAS cancer drug.
Nick Paul Taylor Aug 8, 2024 10:59am
BMS

BMS and Mirati's KRAS inhibitor Krazati moves beyond NSLC

Jun 24, 2024 8:53am
question

ASCO: BMS' confirmatory KRAS data leave FDA prospects unclear

Jun 1, 2024 8:00am
Bristol Myers Squibb

BMS touts KRAS confirmatory trial win after Amgen's stumble

Mar 29, 2024 10:35am
check list to do list yes okay schedule

EU regulators back Mirati's Krazati after initial rebuff

Nov 10, 2023 11:15am
MA

Securities filing details BMS' yearslong courtship of Mirati

Oct 24, 2023 11:41am